The drive for the new generation of vaccine therapies has precipitated a concurrent need for new and improved adjuvantation/delivery systems for these new vaccines. This new international conference will focus on updating the community on new adjuvant/delivery systems/technologies associated with developing modern vaccines strategies and vaccine research. There is now an urgent need for the development of these potent and safe adjuvants and delivery systems and MVADS 2017 will offer researchers a fresh forum to discuss this important topic in detail.

MVADS 2017 will be of interest to researchers/contributors from academic programs, industrial, governmental and regulatory groups.

**ADVISORY SCIENTIFIC PANEL**

Edmund J. Remarque (BPRC, Rijswijk, The Netherlands)
Dennis Christensen (Statens Serum Institut, Copenhagen, Denmark)
Erik Lindblad (Brenntag Biosector, Copenhagen, Denmark)
Rob Lambkin-Williams (hVIVO Ltd, London, UK)
Heather Davis (Seqirus, Maidenhead, Berkshire, UK)
Derek O’Hagan (GSK, Rockville, Maryland, USA)
Adriana Baz Morell (CSL Ltd, Melbourne, Australia)
Nathalie Garcon (BIOASTER Technology Research Institute, Lyon, France)
Niranjan Sardesai (Inovio Pharmaceuticals, Blue Bell, Pennsylvania, USA)
Virgil Schijns (Wageningen University, The Netherlands)
Gary Ott (Dynavax Inc., San Diego, California, USA)
Burkhard Becher (University of Zurich, Zurich, Switzerland)
Maria Lazaro (SEPPIC, Paris, France)
Geert Vanden Bossche (UNIVAC LLC, Belgium)
Steve Reed (IDRI, Seattle, USA)
Martin Bachmann (Inselspital, Bern, Switzerland / University of Oxford, Oxford, UK)
Anna-Karin Maltais (Eurocine Vaccines AB, Solna, Sweden)
Nicolas Havelange (EVI, Heidelberg, Germany)
Jeffrey A. Hubbell (University of Chicago, Chicago, Illinois, USA)
Behazine Combadiere (Clini-Paris, Paris, France)
Ken Ishii (University of Osaka, Osaka, Japan)
Ofer Levy (Boston Children’s Hospital/Harvard Medical School, Boston, Massachusetts, USA)
Jean Haensler (Sanofi Pasteur, Marcy L’Etoile, France)

**CONFERENCE SCOPE**

Scientific Sessions:
Mechanistic Interpretations · Delivery · Formulation & Design · Modern Vaccines & Adjuvants · Safety · Regulation · Future Developments

**CONFERENCE Sponsors**

- Sanofi Pasteur
- NatureGene Therapeutics
- NIH
- Bill & Melinda Gates Foundation
- Janssen
- Atrivax
- Brenntag
- Inovio Pharmaceuticals
- SEPPIC
- IDRI
- Caldevron
- EVI
- UNIVAC
- Novavax
- Seqirus
- BIOASTER
- BIA
- Mucosia
- IZON Science
- Vismederi
- Eurocine
- VAXART
- Myometrics
- CureVac
- BPRC
SESSION 1: OPENING PLENARY

Moderator: Steve Reed
(IDRI, Seattle, Washington, USA)

‘Adjuvants: Where are we now?’
Derek O’Hagan
(GSK, Rockville, Maryland, USA)

‘NK cell-based vaccines: The holy grail of future vaccines?’
Geert van den Bossche
(UniVac LLC, Leuven, Belgium)

‘Biomarkers of human vaccines and adjuvants: Hype and hope’
Ali Harandi
(University of Gothenburg, Gothenburg, Sweden)

Coffee Break & Poster Set-Up

SESSION 2: PLENARY II

Moderator: Derek O’Hagan
(GSK, Rockville, Maryland, USA)

‘Predictive modification of adjuvant activity’
Steve Reed
(IDRI, Seattle, Washington, USA)

‘Inducible adjuvant mediated by multiple, but specific pathways’
Ken Ishii
(NIBIOH/Osaka University, Osaka, Japan)

‘A new generation of a versatile adjuvant A that is delivering, targeting and immune modulating’
Bror Morein, Caroline Fossum and Saideh Berenjian
(Swedish University of Agricultural Sciences (SLU), Uppsala, Sweden)

Lunch Break & Posters

SESSION 3: MUCOSAL I

Moderator: Anna-Karin Maltais
(Eurocine Vaccines AB, Solna, Sweden)

‘Mucosal Vaccines & Adjuvants Overview’
Ali Harandi
(University of Gothenburg, Gothenburg, Sweden)

‘Mucosal Immunity is what’s missing, Dude! Building the Right wall to protect against respiratory and sexually transmitted diseases’
Ali Fattorn, Vira Bitko and Doug Smith (NanoBio Corp., Ann Arbor, Michigan, USA)

‘The oral adjuvant α-Galactosylceramide activates intestinal B cells via an IFN-γ dependent mechanism’
Stephanie Longet¹, Christopher Davitt¹, Joshua Tobias², Jan Holmgren² and Ed C. Lavelle¹
(¹ Trinity College Dublin, Dublin, Ireland; ² University of Gothenburg, Gothenburg, Sweden)

‘Oral immunization for the prevention of norovirus infection’
Sean Tucker
(Vaxart Inc., South San Francisco, California, USA)

SESSION 4: MUCOSAL II

Moderator: Ali Harandi
(University of Gothenburg, Gothenburg, Sweden)

‘Adjuvants targeting STING and the NLRP3 inflammasome to enhance cellular immunity’
Edward Lavelle
(Trinity College Dublin, Dublin, Ireland)

‘Clinical development of an inactivated nasal influenza vaccine’
Anna-Karin Maltais
(Eurocine Vaccines AB, Solna, Sweden)

‘Phase I results of the intranasal RSV vaccine SynGEM’
Maarten van Roosmalen
(Mucosis, Groningen, The Netherlands)

MVADS 2017 Welcome Drinks Reception & Poster Session

LATE-BREAKER ORAL AND POSTER ABSTRACTS

The Scientific Advisory Panel have set an extended deadline for Late-Breaker Oral and Poster Abstracts of Friday 25th August 2017. Prospective authors should submit one page Word documents to the Conference Organizers (Meetings Management) for consideration.

Please send submissions for the attention of John Herriot by e-mail to: jherriot@meetingsmgmt.u-net.com

Late-Breaker Oral and Poster Abstracts should be submitted by Friday 25th August 2017.
**SESSION 5: SPECIAL SESSION**

**PRECISION VACCINES & ADJUVANTS**

Moderators: Ofer Levy
(Boston Children’s Hospital/Harvard Medical School, Boston, Massachusetts, USA)
Martin Bachmann
(Inselspital, Bern, Switzerland / University of Oxford, Oxford, UK)

Sponsored and organized in conjunction with Precision Vaccines Program, Boston Children’s Hospital/Harvard Medical School, Boston, Massachusetts, USA

‘High throughput screening, human in vitro modeling, and systems biology to inform development of novel age-specific adjuvanted vaccines’
Ofer Levy
(Boston Children’s Hospital/Harvard Medical School, Boston, Massachusetts, USA)

‘Discovery and development of Small Molecule Immune Potentiators (SMIPs)’
Derek O‘Hagan
(GSK, Rockville, Maryland, USA)

‘An attempt to develop a universal technology for the development of precision cancer vaccines’
Martin Bachmann
(Inselspital, Bern, Switzerland / University of Oxford, Oxford, UK)

‘Talk to be confirmed’
‘Talk to be confirmed’
Coffee Break & Posters

**SESSION 6: DESIGN & MODELS**

Moderator: Steve Reed
(IDRI, Seattle, Washington, USA)

‘Targeted delivery in rational vaccine design’
Dennis Christensen
(Statens Serum Institut, Copenhagen, Denmark)

‘NHP models for vaccines, adjuvants and delivery systems’
Edmond J. Remarque
(Biomedical Primate Research Centre, Rijswijk, The Netherlands)

‘iVAX: Computationally accelerated human and animal vaccine design’
Oreda Boussadila
(EpiVax Inc., Lyon, France)

‘Self-adjuvanted protein nanoparticles as a platform for vaccine design’
Caroline Kulanagara, Sara M. Paulillo, Senthil K. Raman and Peter Burkhard
(Alpha-O Peptides AG, Riehen, Switzerland)

Lunch Break & Posters

**SESSION 7: ADJUVANTS/VLPS/NANOPARTICLES**

Moderator: Martin Bachmann
(Inselspital, Bern, Switzerland / University of Oxford, Oxford, UK)

‘Novel adjuvants for skin immunization’
Ioanna Skountzou
(Emory University, Atlanta, Georgia, USA)

‘The use of new adjuvants and VLPs for the development of vaccines for emerging and infectious diseases’
Gustavo Cabral de Miranda
(University of Oxford, Oxford, UK)

‘Versatile nanoparticle platform for multifunctional vectorization and epitope delivery’
Pricillia Lagoutte, Adrien Lugari, Gustavo Stadthagen, Charlotte Mignon, Stephanie Donnat, Mourad Bekhouche, Nachata Mariano and Bettina Werle
(Bioaster, Lyon, France)

‘Evaluation of self-assembling protein nanoparticles (SAPN) for multi-antigen display’
Evelina Angov1, Elke S. Bergmann-Leitner1, Zoltan Beck2, Katherine L. Mallory4, Christoph Manni, Neeraja Punde1, David E. Lanan3, Carl Alving2, Gary R. Matyas2 and Peter Burkhard3
(1 Military Malaria Research Program, Malaria Vaccine Branch, Walter Reed Army Institute of Research, Silver Spring Maryland, USA; 2 Military HIV Research Program, Laboratory of Adjuvant and Antigen Research, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA; 3 Alpha-O Peptides AG, Riehen, Switzerland)

‘Novel antigen-carrier system for multi-epitope subunit vaccine candidate against tuberculosis’
Kata Horvati1, Gergő Gyulaí2, Éva Kiss2, Bernadett Pályi3, Zoltán Kis4, Sándor Dávid4, Nóra Szabó1, Kinga Fodor1 and Zsírvia Bőszé3
(1 MTA-ELTE Research Group of Peptide Chemistry, Budapest, Hungary; 2 Laboratory of Interfaces and Nanostructures, Eötvös L. University, Budapest, Hungary; 3 National Biosafety Laboratory, National Center for Epidemiology, Budapest, Hungary; 4 Laboratory of Bacteriology, Korányi National Institute for Tuberculosis, Budapest, Hungary; 5 Department of Veterinary Forensics, Law and Economics, University of Veterinary Medicine, Budapest, Hungary)

‘Vaccination inaging: Beyond the B lymphocyte lineage’
Doron Melamed
(Rappaport Faculty of Medicine, Technion/Israel Institute of Technology, Haifa, Israel)

‘First in human clinical trial of a novel, chemokine fusion DNA cancer vaccine’
Larry W. Kwaki1, Soong-chul Cha1, D. Lynne Smith3, Sapna R. Parshottham2, Chris Hope4, Duarte, California, USA)

‘Effect of QS21 and aluminum hydroxide gel on physical and adjuvant properties of Army liposome formulations’
Zoltan Beck1,2, Carl Alving2 and Victoria Polonis3
(US Military HIV Research Program: 1 Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, USA; 2 Laboratory of Adjuvant and Antigen Research; 3 Laboratory of Vaccine Immunology, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA)

**SESSION 8: VACCINES/VACCINATION**

Moderator: Heather Davis
(Sequins, Maidenhead, Berkshire, UK)

‘Soluble glycopolymer conjugates as nanovaccines’
Jeffrey A. Hubbell
(University of Chicago, Chicago, Illinois, USA)

‘Title to be confirmed’
Heather Davis
(Sequins, Maidenhead, Berkshire, UK)

‘MACIVIVA: Manufacturing of cold-chain independent virosome-based vaccine’
Mario Armaccker, Sylvain Fleury and Toen Steggmann
(Mymetics SA, Epalinges, Switzerland)

‘Novel antigen-carrier system for multi-epitope subunit vaccine candidate against tuberculosis’
Kata Horvati1, Gergő Gyulaí2, Éva Kiss2, Bernadett Pályi3, Zoltán Kis4, Sándor Dávid4, Nóra Szabó1, Kinga Fodor1 and Zsírvia Bőszé3
(1 MTA-ELTE Research Group of Peptide Chemistry, Budapest, Hungary; 2 Laboratory of Interfaces and Nanostructures, Eötvös L. University, Budapest, Hungary; 3 National Biosafety Laboratory, National Center for Epidemiology, Budapest, Hungary; 4 Laboratory of Bacteriology, Korányi National Institute for Tuberculosis, Budapest, Hungary; 5 Department of Veterinary Forensics, Law and Economics, University of Veterinary Medicine, Budapest, Hungary)

‘Vaccination in aging: Beyond the B lymphocyte lineage’
Doron Melamed
(Rappaport Faculty of Medicine, Technion/Israel Institute of Technology, Haifa, Israel)

‘First in human clinical trial of a novel, chemokine fusion DNA cancer vaccine’
Larry W. Kwaki1, Soong-chul Cha1, D. Lynne Smith3, Sapna R. Parshottham2, Chris Hope4, Duarte, California, USA)

‘Effect of QS21 and aluminum hydroxide gel on physical and adjuvant properties of Army liposome formulations’
Zoltan Beck1,2, Carl Alving2 and Victoria Polonis3
(US Military HIV Research Program: 1 Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, USA; 2 Laboratory of Adjuvant and Antigen Research; 3 Laboratory of Vaccine Immunology, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA)
SESSION 9: ADJUVANTS ACTIVITY

Moderator: Ken Ishii
(NIBIOH/Osaka University, Osaka, Japan)

‘Characterization of the adjuvant activity of linear polyacrylates’
Jean Haensler1, Marie Garinot2, Yuanqing Liu2, Fabienne Piras3, Virginie Courtois3, Premkumar Dinadayala4, Etodle Belnoue5, Floriane Auderset6, Beatris Masticel-Gavillet7 and Claire-Anne Siegrist8
(1 Sanofi Pasteur, Marcy l’Etoile, France; 2 CMU- University of Geneva, Geneva, Switzerland)

‘Adjuvant properties of the novel toll-like receptor 7 and 8 agonist 3M-052’
Mark Tomai (3M Company, St Paul, Minnesota, USA)

‘Prospect of chemically modified aluminum phosphate adjuvant’
Laurent Duroux
(Brenntag Bioscector, Frederikssund, Denmark)

‘Selection of a novel MPLA and QS-21 containing liposomal adjuvant, ALFQ, for a circumsporozoite protein based malaria vaccine, FMP013’
Sheetij Dutta2, Christopher J. Genito1, Zoltan Beck3, Alicia D. Cawlfield2, Edward Remarque
(1 Institute for Translational Vaccinology, Bilthoven, The Netherlands; 2 Institute for Public Health and the Environment, Bilthoven, The Netherlands)

SESSION 10: FORMULATION & DELIVERY

Moderator: Mannohman Singh
(Takeda vaccines Inc., Cambridge, Massachusetts, USA)

‘Outer membrane vesicles as delivery system for Bordetella pertussis antigens’
R. Raeven1, J. Brummelman2, J. Pennings2, E. van Riet1, C. van Els2, W. Han2, B. Metz2 and G. Kersten1
(1 Institute of Translational Vaccinology, Bilthoven, The Netherlands; 2 Institute for Public Health and the Environment, Bilthoven, The Netherlands)

‘NHP models for adjuvants and delivery systems’
Edward Remarque
(Biomedical Primate Research Centre, Rijswijk, The Netherlands)

‘Breaking the barrier of proprietary adjuvants and delivery systems’
Kenneth Bertram
(US Army Medical Research and Material Command, Fort Detrick, Maryland, USA)

‘Formulation and delivery of a dual COX-2/5-LO inhibitor in combination with a therapeutic cancer vaccine’
Blake Gibson1, David Larsen2 and Sarah Hook1
(1 School of Pharmacy, University of Otago, Dunedin, New Zealand; 2 Department of Chemistry, University of Otago, Dunedin, New Zealand)

LATE-BREAKER ORAL AND POSTER ABSTRACTS

The Scientific Advisory Panel have set an extended deadline for Late-Breaker Oral and Poster Abstracts of Friday 25th August 2017. Prospective authors should submit one page Word documents to the Conference Organizers (Meetings Management) for consideration.

Please send submissions for the attention of John Herriot by e-mail to: jherriot@meetingsmgmt.u-net.com

Late-Breaker Oral and Poster Abstracts should be submitted by Friday 25th August 2017.

* This provisional programme is correct at the time of publication. However the organizers reserve the right to make any alterations that may be required in the interests and integrity of the conference programme.
REGISTRATION

Delegates should register for MVADS 2017 by completing the form provided on the back page of this brochure. The completed Conference Registration Form plus payment (payment in £ Pounds Sterling) should be sent to the MVADS 2017 Conference Manager – Caroline Sumner at Meetings Management. The MVADS 2017 Conference Registration Desk will be open from 7.30am on Tuesday 12th September 2017.

Delegates can also register securely on-line at: http://www.meetingsmanagement.com/mvads_2017

VENUE & ACCOMMODATION

The venue for MVADS 2017 is the Crowne Plaza Hotel in Porto, Portugal.

CROWNE PLAZA HOTEL
Avenida da Boavista, 1466 4100-114 Porto, Portugal
Tel: +351 22 607 2500  Fax: +351 22 600 3214
Email: candida.baldaia@ihg.com
Web: www.crowneplaza.com/porto

To book accommodation at the Crowne Plaza Hotel please go to the MVADS 2017 website and click on the Accommodation link to access the hotel booking form:

http://www.meetingsmanagement.com/mvads_2017

Preferential rates have been agreed for MVADS 2017 delegates.

PUBLICATION

A USB memory stick of final programme and abstracts of all presentations, oral and poster, will be distributed to delegates when they register at the conference.

TABLE TOP EXHIBITION

Table Top Exhibition space is available at the meeting. Exhibitors can showcase their products or services by reserving a table top exhibit. The exhibit area will be located where all refreshments breaks will be taken to ensure maximum traffic of conference delegates. If you are registering for the conference, you can reserve a table for £1500. If you do not wish to attend the conference sessions, you can reserve a table for £2500 (includes admission to all meals/receptions by one company representative).

PLEASE NOTE: If you wish to have additional representatives on your table top exhibit there will be an additional charge levied per head. Please contact the Conference Manager for this additional price.

Please make your bookings and payment using the relevant section on the Delegates Registration Form on the back page of this brochure. All general enquiries regarding Table Top Exhibition facilities at MVADS 2017 should be directed to John Herriot at Meetings Management (E-mail: jherriot@meetingsmgmt.u-net.com).

DELEGATE PACK INSERT SERVICE

Company literature/brochures/conference brochures may be distributed to delegates as part of the documentation issued on arrival/registration. One insertion in the MVADS 2017 delegate pack is priced at £450. Please make your booking and payment using the relevant section on the Delegates Registration Form on the back page of this brochure. All general enquiries regarding Delegate Pack Insertion services at MVADS 2017 should be directed to John Herriot at Meetings Management (E-mail: jherriot@meetingsmgmt.u-net.com).

PLEASE NOTE: Literature for distribution to MVADS 2017 delegates is subject to approval by the conference organizers.

INSURANCE & CANCELLATION

The organizers cannot be held responsible for any personal accident or damage to their private property of participants at MVADS 2017. The organizers strongly urge participants to ensure they have adequate travel and personal insurance cover before they depart for the conference. The organizers cannot be held liable for any costs incurred should the conference be cancelled for any reason. Maximum notice of cancellation will be given by the organizers to all pre-registered delegates.

PROGRAMME

The MVADS 2017 Advisory Scientific Panel and the MVADS 2017 Conference Organizers reserve the right to alter any part of the published conference programme if this is necessitated by any circumstances outside their control. All efforts will be made to keep any such changes to a minimum. The programme published in the brochure was correct at the time of going to press.

CANNOT ATTEND?

If you and your colleagues are unable to attend the conference, the conference materials (abstract booklet, speaker handouts, late abstracts, attendee list, pack materials and literature) are available for purchase. While not intended as a substitute for actual attendance, these materials would at least provide a documentary record of the event and allow you to keep you or your organization’s library up to date. The cost of providing this non-attendee package is £395 (including postage and packing). To order this package from Meetings Management please use the relevant section in the Delegates Registration Form on the back page of this brochure.

ANY QUESTIONS?

For further information and assistance, please contact: Caroline Sumner MVADS 2017 Conference Manager:

MVADS 2017 Conference Secretariat, Meetings Management
The Old Dairy Tower, Peper Harow Park, Godalming, Surrey GU8 6BD, United Kingdom.
Telephone: +44 (0)1483 427770  Fax: +44 (0)1483 428516
E-mail: csumner@meetingsmgmt.u-net.com

LATE-BREAKER ORAL AND POSTER ABSTRACTS

The Scientific Advisory Panel have set an extended deadline for Late-Breaker Oral and Poster Abstracts of Friday 25th August 2017. Prospective authors should submit one page Word documents to the Conference Organizers (Meetings Management) for consideration.

Please send submissions for the attention of John Herriot by e-mail to: jherriot@meetingsmgmt.u-net.com

Late-Breaker Oral and Poster Abstracts should be submitted by Friday 25th August 2017.
Please tick appropriate boxes and write clearly in BLOCK CAPITALS or type.

Surname ........................................ First Name ........................................ Title ........................................
Organization ........................................ Address ........................................
____________________________________________________________________________________
____________________________________________________________________________________
Country ........................................ Telephone ........................................ Fax ........................................
E-mail (plain type or print): ........................................
If you are an EC business please state your VAT registration number: ........................................
Disabled (please state any special needs): ........................................ Special diet (please state requirements): ........................................

REGISTRATION FEES

Speaker/Delegate Registration Fees: (Please tick appropriate section)

☐ Speaker Registration (submitted oral/poster papers) £645.00 £
(Payment must be received before Friday 26th May 2017)

☐ Reduced Early Bird Registration £760.00 £
(Payment must be received before Friday 26th May 2017)

☐ Full Registration £875.00 £
(Payment received after Friday 26th May 2017)

☐ Student Registration Price on application £

Table Top Exhibits/Delegate Pack Inserts

☐ Table Top Exhibit (if registering for one of the four options above) £1500.00 £

☐ Table Top Exhibit (I am NOT registered to attend) £2500.00 £

☐ Delegate Pack Insert £450.00 £

PLEASE NOTE: The above payments for Table Top Exhibits are for 1 company representative only. If you require additional representatives please contact the Conference Manager for a price.

For those Unable to Attend

☐ Set(s) of MVADS 2017 materials @ £395.00 (per set) £

Total Amount Payable £

Registration fees include admission to all conference sessions, morning and afternoon refreshments and lunches on the 12th, 13th and 14th September 2017.

PAYMENT

☐ I enclose a cheque for £ ........... made payable to Meetings Management. (Delegates registering from outside the UK must ensure that cheques are drawn on a London Bank. Please quote MVADS 2017 on the reverse of the cheque.)

☐ I have made a payment by bank transfer (quoting MVADS 2017 on the transfer documentation) to Barclays Bank, Barclays Business Centre, Guildford Branch, PO Box 33, Guildford, Surrey GU1 3AN, UK:

UK Pounds Sterling Account: Meetings Management 0040614335, IBAN GB02BARC20353540614335 SWIFTBIC BARCG22
US Dollar Account: Meetings Management 53209211, IBAN GB77BARC20353S53209211 SWIFTBIC BARCG22
Euro Account: Meetings Management 59179600, IBAN GB91BARC2035359179600 SWIFTBIC BARCG22

All transfer charges must be paid by the sender. Delegates paying by this method are requested to send the Conference Manager a copy of the bank transfer. Payments made by bank transfer must have £15.00 added to the total. PLEASE NOTE THAT IT WILL NOT BE POSSIBLE TO PAY REGISTRATION FEES BY BANK TRANSFER AFTER FRIDAY 30TH JUNE 2017. LATE PAYMENT AFTER FRIDAY 30TH JUNE 2017 MUST BE MADE BY CREDIT CARD (VISA/MASTERCARD/AMEX).

☐ I would like to pay £ ........... by credit card (VISA/MasterCard/AMEX Express only accepted).


Expiry Date .......................... Registered Card Address ..........................

Please remember that any remittance sent but not received by the time of the conference must be paid again at the Registration desk: we will refund you after the conference. Cancellations received before Friday 30th June 2017 will be refunded in full less an administrative charge of £225 per person. Refunds will not be possible if a cancellation is received after Friday 30th June 2017. Substitutions can be made at any time prior to the conference. Please inform the Conference Manager of any changes. We strongly advise that delegates purchase travel insurance to cover any unforeseen circumstances and protect against loss of hotel deposits and registration fees.

Signature ........................................ Date ........................................

PLEASE RETURN THIS FORM TO:

MVADS 2017 CONFERENCE SECRETARIAT, MEETINGS MANAGEMENT
The Old Dairy Tower, Peper Harow Park, Godalming, Surrey GU8 6BD, United Kingdom
Conference Manager: Caroline Sumner Telephone: +44 (0)1483 427770 Fax: +44 (0)1483 428516 E-mail: csunner@meetingsmgmt.u-net.com

SECURE ON-LINE REGISTRATION IS NOW OPEN AT: www.meetingsmanagement.com/mvads_2017